Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 18 of the 25 sources its claims cite were checked for support.

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.

Open access

Published version of a preprint

Abstract

Most patients with KRASG12C–mutant non–small cell lung cancer (NSCLC) experience clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer bearing the same mutation rarely respond. To investigate the cause of the limited efficacy of KRASG12C inhibitors in colorectal cancer, we examined the effects of AMG510 in KRASG12C colorectal cancer cell lines. Unlike NSCLC cell lines, KRASG12C colorectal cancer models have high basal receptor tyrosine kinase (RTK) activation and are responsive to growth factor stimulation. In colorectal cancer lines, KRASG12C inhibition induces higher phospho-ERK rebound than in NSCLC cells. Although upstream activation of several RTKs interferes with KRASG12C blockade, we identify EGFR signaling as the dominant mechanism of colorectal cancer resistance to KRASG12C inhibitors. The combinatorial targeting of EGFR and KRASG12C is highly effective in colorectal cancer cells and patient-derived organoids and xenografts, suggesting a novel therapeutic strategy to treat patients with KRASG12C colorectal cancer. Significance: The efficacy of KRASG12C inhibitors in NSCLC and colorectal cancer is lineage-specific. RTK dependency and signaling rebound kinetics are responsible for sensitivity or resistance to KRASG12C inhibition in colorectal cancer. EGFR and KRASG12C should be concomitantly inhibited to overcome resistance to KRASG12C blockade in colorectal tumors. See related commentary by Koleilat and Kwong, p. 1094. This article is highlighted in the In This Issue feature, p. 1079

Overview

CoChat Summary

TL;DR

In KRAS G12C colorectal cancer, EGFR signaling drives resistance to KRAS G12C inhibition: CRC cells show high basal RTK activation and rapid phospho-ERK rebound after AMG510, unlike NSCLC. Combining EGFR blockade with AMG510 durably suppresses signaling and induces tumor regression in CRC cell lines, patient-derived organoids, and xenografts.

Key findings

  • AMG510 initially downregulated phospho-ERK in all models, but after 24 hours NSCLC lines further downregulated ERK phosphorylation while all CRC lines showed phospho-ERK rebound; in C106, residual phospho-MEK/ERK was measurable after 1 hour, whereas NCIH358 rebound appeared only at 72 hours.
  • In 8 CRC and 5 NSCLC KRAS G12C patient specimens analyzed for 72 proteins by SRM-mass spectrometry, EGFR, HER2, and MET were detectable in both lineages, HER3 was more prevalent in CRC, and ALK, ROS1, RET, FGFR, or AXL were not detected; two CRC and two NSCLC patients later treated with AMG510 showed clinical benefit only in the NSCLC cases.
  • EGFR was identified as the dominant resistance mechanism: cetuximab plus AMG510 synergized in CRC cell lines, sustained inhibition of phospho-MEK/phospho-ERK and DUSP6/CyclinD1, and induced cytotoxicity; combination was also effective in LIM1215 KRAS G12C knock-in clones and the HCA46-R Pmab secondary-resistance model.
  • In patient-derived models, single-agent AMG510 or cetuximab poorly inhibited three KRAS G12C PDOs while the combination suppressed proliferation with high synergy; in two KRAS G12C PDXs, combination treatment induced massive or complete tumor shrinkage, with no tumor visible after 10 weeks, and Ki67 IHC intensity was 97% in vehicle, 92% in cetuximab, and 83% in AMG510 samples, with strong phospho-ERK only in AMG510-treated samples.

Methods

  • Preclinical study using KRAS G12C mutant NSCLC and CRC cell lines, dose-response proliferation assays, Western blotting, phospho-RTK arrays, EGFR immunoprecipitation, RAS-GTP pull-down, and SRM-mass spectrometry of 72 biomarkers in FFPE tissue from 8 CRC and 5 NSCLC patient specimens.
  • Patient-derived models included three KRAS G12C mutant CRC PDOs plus one KRAS G12D mutant PDO as negative control, and two KRAS G12C mutant CRC PDXs; in vivo dosing was AMG510 100 mg/kg daily by gavage and cetuximab 50 mg/kg twice weekly intraperitoneally, with mice randomized to treatment or vehicle.
  • Main analyses included ATP-based CellTiter-Glo viability, CellTox Green cytotoxicity, crystal violet long-term proliferation, Bliss synergy scoring, Ki67 and phospho-ERK IHC, and densitometry with ImageJ and GraphPad Prism.

Limitations

  • Stated: the authors note that in clinical samples they could not assess activated RTK levels or evaluate the functional consequences of detectable RTK expression.
  • Evident: the clinical correlation rests on only two CRC and two NSCLC patients who later went on the AMG510 phase 1 trial, and the paper does not include a dedicated limitations section.
  • Evident: the efficacy of combined EGFR and KRAS G12C inhibition is shown in cell lines, PDOs, and PDXs, not in a clinical trial, and the PDX experiments use small group sizes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-0187

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

12 Valid · 0 Not valid · 1 Not checked · 69 Own results and interpretations

45 more claims

Create a free account to see all 82 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 12
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

54 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 39 references

Cited by

See all 504

Metadata

Authors
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., Whaley, A., Pinnelli, M., Murciano-Goroff, Y. R., Vakiani, E., Valeri, N., Liao, W.-L., Bhalkikar, A., Thyparambil, S., Zhao, H.-Y., de Stanchina, E., Marsoni, S., Siena, S., Bertotti, A., Trusolino, L., Li, B. T., Rosen, N., Di Nicolantonio, F., Bardelli, A., & Misale, S.
Affiliations
  • Candiolo Cancer Institute (IT)
  • Memorial Sloan Kettering Cancer Center (US)
  • 3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Institute of Cancer Research (GB)
  • 8mProbe Inc., Rockville, Maryland.
  • 4Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
  • University of Milan (IT)
  • 1Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Venue
Cancer Discovery
Published
2020-08-01
Volume
10
Issue
8
Pages
1129-1139
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3028041439
Cited by
504
References
39
Citations by year
2026: 85 · 2025: 88 · 2024: 98 · 2023: 73 · 2022: 81 · 2021: 66 · 2020: 13
FWCI
21.03
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
  • Associazione Italiana per la Ricerca sul Cancro (20697, 21407, 22802)
  • AIRC (IG 2018-ID 21923, 2018-ID 21091, 2017 ID 20236)
  • European Research Council (724748)
  • H2020 (754923, 731105)
  • AIRC CRUK AECC (22795)
  • NIH (R01 CA233736)
  • Cancer Center Core (P30 CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
KRAS G12C, colorectal cancer, EGFR, drug resistance, sotorasib, receptor tyrosine kinase signaling, combination therapy, patient-derived organoids, xenografts
MeSH terms
Cetuximab, Animals, Antineoplastic Agents, Female, Humans, Piperazines, Pyridines, Pyrimidines, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Mice, SCID, Drug Resistance, Neoplasm, Cell Line, Tumor, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-0187
The paper
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., Whaley, A., Pinnelli, M., Murciano-Goroff, Y. R., Vakiani, E., Valeri, N., Liao, W.-L., Bhalkikar, A., Thyparambil, S., Zhao, H.-Y., . . . Misale, S. (2020). EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0187

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.